What is the main purpose of the amendment to the transaction agreement with Abbott Laboratories?

The amendment modifies the terms under which Abbott will supply everolimus eluting stents to Boston Scientific in Europe and clarifies the licensing of intellectual property related to Guidant's drug-eluting stent program. This aims to adjust supply timelines and intellectual property usage rights in anticipation of the Guidant acquisition and BSX's own product development.

How does this amendment affect Boston Scientific's ability to sell drug-eluting stents in Europe?

The amendment sets specific termination dates for Abbott's supply of everolimus eluting stents to BSX in Europe. It also clarifies that the intellectual property license will be non-exclusive, except for everolimus eluting stent systems where it is co-exclusive. This gives BSX more control and flexibility over its European stent strategy.

What is the significance of withdrawing and refiling the HSR notification for the Guidant transaction?

Withdrawing and refiling the Hart-Scott-Rodino (HSR) notification is a procedural step taken to address antitrust concerns raised by the Federal Trade Commission (FTC) staff. Entering into consent orders and refiling the notification indicates that BSX is actively working with regulators to resolve any potential competitive issues, which is essential for the consummation of the Guidant acquisition.

Are there any changes to the intellectual property rights for Guidant's drug-eluting stent technology?

Yes, the amendment specifies that the license from Abbott to BSX for Guidant's drug-eluting stent IP will be non-exclusive. However, it will be co-exclusive for everolimus eluting stent systems, meaning that any rights Abbott grants to a third party for their drug-eluting stent system will not extend to systems using everolimus as the drug.

BSX 8-K: Material Agreements

Summary

This 8-K filing from Boston Scientific Corporation (BSX) on April 7, 2006, details two significant developments impacting its proposed acquisition of Guidant Corporation and its relationship with Abbott Laboratories. The company entered into an amendment to its transaction agreement with Abbott, modifying the terms related to the supply and licensing of everolimus eluting stents in Europe. This amendment adjusts Abbott's supply obligations and clarifies the exclusivity of intellectual property licenses, which is crucial for BSX's European market strategy for drug-eluting stents.

Key Highlights

1Amendment to Transaction Agreement with Abbott Laboratories regarding everolimus eluting stents for the European market.
2Abbott's obligation to supply everolimus eluting stents to BSX in Europe will terminate under specific conditions, including 90 days after a European Commission design examination certificate is issued for a BSX-developed stent.
3The license granted by Abbott to BSX for Guidant's drug-eluting stent intellectual property will be non-exclusive, with a co-exclusive provision for everolimus eluting stent systems.
4Abbott will have an exclusive right to sublicense certain Guidant vascular and endovascular intellectual property assets licensed from BSX.
5BSX has entered into consent orders with the FTC staff regarding the proposed combination with Guidant.
6BSX will voluntarily withdraw and refile its HSR notification for the Guidant transaction around April 7, 2006.
7These actions are critical steps in addressing regulatory concerns and finalizing the acquisition of Guidant.

BOSTON SCIENTIFIC CORP 8-K Report, Material Agreement (Apr 7, 2006)

Summary

Key Highlights

Frequently Asked Questions